Lixte Biotechnology Holdings Inc. (LIXT:NSD) STA Research assigns a Spec Buy rating, $1.40 stock target

STA Research assigned a Speculative Buy rating on Lixte Biotechnology with a 12 month target forecast of $1.40 per share on the equity.

Based on the Lixte Biotechnology Holdings Inc stock (lixt stock price) forecasts from 1 analysts, the average analyst target price for Lixte Biotechnology Holdings Inc (lixt stock price) is $1.40 over the next 12 months. Lixte Biotechnology Holdings Inc’s average analyst rating is Speculative Buy . Stock Target Advisor’s own stock analysis of Lixte Biotechnology Holdings Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Lixte Biotechnology Holdings Inc’s stock price was USD 0.73. Lixte Biotechnology Holdings Inc’s stock price has changed by -0.03% over the past week, -0.03% over the past month and -75.86% over the last year.

Lixte Biotechnology Holdings, Inc. is a drug discovery firm that develops innovative drugs to target enzyme targets linked to major common diseases using biomarker technologies. The business is headquartered in Pasadena, California, and was established in 2005.

 

What we like:

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like:

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector